Key result
FK506 immunosuppression enabled the survival of transplanted myoblasts expressing beta-galactosidase for up to 12 weeks in monkeys, compared to no survival at 4 weeks without immunosuppression.
Why the study?
Does FK506 immunosuppression improve the survival of transplanted myoblasts and reduce immune response in monkeys?
Population
14 monkeys receiving myoblast transplantation
Comparison
Immunosuppression with FK506 (n=6) vs No immunosuppression (n=8)
Design
Preclinical
Follow-up
12 weeks
Authors
Loading...
Should not change clinical practice; hypothesis-generating for FK506-assisted myoblast transplantation in primates.
Does FK506 immunosuppression improve the survival of transplanted myoblasts and reduce immune response in monkeys?
FK506 effectively controls short-term immune reactions following myoblast transplantation in monkeys, suggesting potential utility for Duchenne Muscular Dystrophy patients.
Kinoshita et al. (1996) studied Myoblast transplantation (n=14). FK506 vs. No immunosuppression was evaluated on Presence of muscle fibers expressing beta-galactosidase. FK506 immunosuppression enabled the survival of transplanted myoblasts expressing beta-galactosidase for up to 12 weeks in monkeys, compared to no survival at 4 weeks without immunosuppression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: